TRDA VS AORT Stock Comparison
Performance
TRDA10/100
10/100
TRDA returned -10.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
AORT51/100
51/100
AORT returned 13.17% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 50 of 100.
Technicals
TRDA71/100
71/100
TRDA receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.
AORT50/100
50/100
AORT receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
TRDA10/100
10/100
TRDA has missed earnings 4 times in the last 20 quarters.
AORT29/100
29/100
AORT has missed earnings 4 times in the last 20 quarters.
Profit
TRDA10/100
10/100
Out of the last 13 quarters, TRDA has had 1 profitable quarters and has increased their profits year over year on 1 of them.
AORT16/100
16/100
Out of the last 20 quarters, AORT has had 3 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
TRDA51/100
51/100
TRDA has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
AORT47/100
47/100
AORT has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Entrada Therapeutics, Inc. Common Stock Summary
Nasdaq / TRDA
Healthcare
Biotechnology
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Artivion, Inc. Summary
New York Stock Exchange / AORT
Healthcare
Medical - Devices
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare TRDA to other companies in the same or a similar industry.